vimarsana.com

Spurwing Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for

ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - April 19, 2024

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.